TAIHO PHARMACEUTICAL CO., LTD.
- Country
- π―π΅Japan
- Ownership
- Subsidiary
- Established
- 1963-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.taiho.co.jp
Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT00824161
- Locations
- πΊπΈ
NYU Cancer Institute, East 34th Street, New York, New York, United States
πΊπΈThe Center for Cancer and Blood Disorders, West Magnolia Avenue, Fort Worth, Texas, United States
πΊπΈThe University of Texas M.D. Anderson Cancer Center, Holcombe Boulevard, Houston, Texas, United States
Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2012-03-26
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT00784290
- Locations
- π―π΅
Chiba University Hospital, Inohana Chuo-ku Chiba, Chiba, Japan
Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 375
- Registration Number
- NCT00770874
- Locations
- π¨π³
Chang Gung Medical Foundation- Linkou, Fu-Hsing Saint Kuei Shan Hsiang, TaoYuan Hsien, Taiwan
π―π΅Yanagawa Hospital, Chikushimachi, Yanagawa, Fukuoka, Japan
π―π΅Cancer Institute Hospital, Ariake, Koto-ku, Tokyo, Japan
Phase II Study of TAS-106 to Treat Head and Neck Cancer
- First Posted Date
- 2008-08-19
- Last Posted Date
- 2012-09-05
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 27
- Registration Number
- NCT00737360
- Locations
- πΊπΈ
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Orleans Street, Baltimore, Maryland, United States
πΈπ¬National University Hospital, Lower Kent Ridge Road, Singapore
π¨π³National Taiwan University Hospital Department of Oncology, No. 1, Chang-De Street , Taipei, Taiwan
Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-07-25
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT00721916
- Locations
- π―π΅
Shizuoka Cancer Center, Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, Japan
Phase II Study of ABI-007 for Gastric Cancer
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT00661167
- Locations
- π―π΅
Kochi Health Sciences Center, Kochi, Japan
π―π΅Aichi Cancer Center, Nagoya, Aichi, Japan
π―π΅National Kyusyu Cancer Center, Fukuoka, Japan
Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer
- First Posted Date
- 2007-12-07
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT00569335
- Locations
- π―π΅
National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan
Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)
- First Posted Date
- 2007-12-07
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT00569699
- Locations
- π―π΅
Osaka Medical College Hospital, Takatsuki, Osaka, Japan
Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer
- First Posted Date
- 2007-12-07
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 53
- Registration Number
- NCT00569790
- Locations
- π―π΅
Hokkaido University Hospital (Hokkaido Gastrointestinal Cancer Study Group), Sapporo, Hokkaido, Japan
Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 834
- Registration Number
- NCT00498225
- Locations
- π¨π³
Chang Gung Memorial Hospital, Kaohsiung, No.123, Ta-Pei Rd., Niao-Sung Hsiang, Kaohsiung Hsien, Taiwan
π¨π³Chung-Ho Memorial Hospital, Kaohsiung Medical University, No.100, Tzyou 1st Rd., Kaohsiung, Taiwan
π―π΅National Cancer Center Hospital, Tokyo, Japan